BCD Bioscience, Inc.

Established: 2019
Location: Davis, CA
Prior Round Funding: Series A

Established:
Location:
Prior Round Funding:

BCD Bioscience discovers, develops and understands naturally occurring carbohydrate based prebiotics that enable unprecedented control of the microbiome for beneficial health and nutritional outcomes.

Cocoon Biotech, Inc.

Established: 2013
Location: Cambridge, MA
Prior Round Funding: Seed

Established:
Location:
Prior Round Funding:

Cocoon Biotech is a biomaterials company that uses fibroin, a protein derived from the cocoon of the silkworm, to both replace unsustainable ingredients and provide the foundation for a new generation of innovative products.

Cofactor Genomics, Inc.

Established: 2008
Location: St. Louis, MO
Prior Round Funding: Series A

Established:
Location:
Prior Round Funding:

Cofactor Genomics is a precision medicine company that focuses on RNA for its understanding of disease – initially cancer but with applicability across many diseases.

Cyrus Biotechnology

Established: 2014
Location: Seattle, WA
Prior Round Funding: Series B

Established:
Location:
Prior Round Funding:

Cyrus Biotechnology is a drug discovery company that has developed and is employing innovative protein design software to make highly differentiated therapeutics. The company is building both internal and partnered protein biologics that are engineered to be safer, longer lived, more efficacious and more readily manufactured than those currently available.

Entac Medical, Inc.

Established: 2015
Location: Germantown, TN
Prior Round Funding: Series B

Established:
Location:
Prior Round Funding:

Entac Medical is developing noninvasive devices for predictive and diagnostic medicine based on a novel, patented, platform technology, Previs Audio Spectral Analysis. Their first product is used to predict post operative ileus after GI surgeries.

Euclises Pharmaceuticals, Inc.

Established: 2012
Location: St. Louis, MO
Prior Round Funding:

Established:
Location:
Prior Round Funding:

Euclises Pharmaceuticals is developing novel enzyme (COX-2) inhibitors designed to increase the effectiveness of chemotherapy safely

Evolve Biosystems

Established: 2012
Location: Davis, CA
Prior Round Funding: Series D

Established:
Location:
Prior Round Funding:

Evolve Biosystems is an infant nutrition that develops microbial products that are key to the development of gut & immune health.

Faeth Therapeutics

Established: 0
Location: San Francisco, CA
Prior Round Funding: Series A

Established:
Location:
Prior Round Funding:

Overview

Faeth Therapeutics, Inc (“Faeth” of the “Company”) is clinical stage biotechnology company targeting cancer therapeutics. Faeth’s highly personalized precision nutrition program is designed to deprive tumors of the nutrients they need to grow. The Faeth Program includes meals, therapeutics, and on-demand support from Faeth nutritionists

Problem & Opportunity

More than 1.6 million people in the US are diagnosed with cancer each year, and close to 600,000 people die from it, making cancer the second leading cause of death.[1]

For many years, cancer has been thought of primarily as a genetic disease. New research suggests that while genetics may initiate cancers, it is metabolic interactions that cause the tumors to thrive and proliferate. Cancer cells grow continuously and rapidly, and they do this with metabolic processes that are distinct from that of healthy cells.[2]

Given that the research on the metabolic nature of tumors is new, researchers have not deployed this knowledge in the form of approved therapies. Oncologists have instead traditionally relied on the four pillars of cancer treatment: surgery, radiation, small molecules (targeted therapies or radiation), and increasingly immunotherapy (targeting the immune system to detect and kill cancers).

Solution & Technology

Faeth is developing a paradigm shift in oncology: using our metabolism to beat cancer through nutrition. The founders (see Team below) are world class researchers in oncology and have found that pairing a precision nutrition regiment with a known cancer therapeutic (chemotherapy, radiation, etc.) can greatly improve the efficacy of the therapeutic.

Faeth has three main components:

1. Precision nutrition (e.g., an insulin suppressing diet or the targeted elimination of certain amino acids that have been implicated in tumor growth)
2. Pairing the precision nutrition protocol with a known therapeutic intervention that has been shown to be more effective in animal models with a precision nutrition regiment
3. Software and mobile application for patients to find treatment information, improve compliance, and build community

Faeth’s first three assets are in Phase 1 clinical trials. The first clinical trial pairs an insulin suppressing diet with a known cancer therapeutic that the Company has licensed from Takeda. The second two programs involve an amino acid restricted diet with existing and approved chemotherapies. These clinical trials are currently for pancreatic, colorectal, ovarian, and endometrial cancers, with more therapies in preclinical studies addressing other cancers.

Business Model & Commercial Traction

Faeth’s therapies are not currently in market. However, the Company has convened reimbursement panels consisting of representatives from large insurance companies, including Blue Cross Blue Shield and Aetna. The payer panel indicated that Faeth, based on other approved drugs in adjacent markets, is well positioned to receive reimbursement for its cancer therapies.

Competition & Differentiation

Faeth’s is the first of its kind in its metabolic approach to cancer treatment. Historically, cancer has been treated by surgery, radiation, drugs, or immunotherapies. Cancer drugs have predominantly focused on mutating growth signaling through small molecules. Some historical approaches focused on the metabolic pathways themselves, but Faeth’s approach is novel in that it goes upstream and focuses on controlling nutrients.

Deal Summary

Faeth is raising $55M of Series A Preferred Stock at a $165M pre-money valuation led by S2G Ventures (Benson Hill, Arable, et al.). Other participants include Khosla Ventures, Future Ventures, and Digitalis Ventures. Proceeds from the round will be used for continuing the clinical trials for its first three assets, R&D, and G&A. The Offering will close on September 14^th, 2022 but iSelect needs to notify the Company of our interest by early June 2022.

If you have further questions, please reach out to your iSelect representative. Please let us know at your earliest convenience if you would like to participate.

Investment Disclaimer

Investments in private placements are speculative, illiquid and carry the risk of complete loss. In addition to the foregoing risks, the adverse economic effects of the COVID-19 pandemic are unknown and could materially impact this investment. Certain securities as designated are offered through North Capital Private Securities, member FINRA / SIPC. This document does not constitute an offer to sell or a solicitation of an offer to buy any security or interest in any fund or other issuer which can only be made through official offering documents that contain important information about risks, fees and expenses. Any investment information contained herein has been secured from sources we believe are correct, but we make no representations or warranties as to the accuracy of such information and accept no liability thereof. The information contained herein is subject to discussion, completion and amendment.

Red Herring Disclaimer

Faeth Therapeutics, Inc. (the “Company”) is seeking financing but has not obtained definitive investment documents for any such financing at this time. Moreover, iSelect Fund Management, LLC has not completed its due diligence review and approval of an investment in the Company. This information is being provided to you now because there is likely to be a short period of time between reaching definitive terms on any financing and the time when investors are required to decide to participate in such financing. Information contained herein is subject to completion or amendment. No securities for any proposed offering for the Company may not be sold nor may offers to buy be accepted prior to the time the definitive investment documents are provided for all investors to review.

Any final offer and sale of securities of Faeth Therapeutics, Inc. shall be subject to completion of the due diligence requirements set forth by the iSelect Investment Committee, including a review of a final Securities Purchase Agreement setting forth the full terms of such offering.

Existing Investors

Khosla Ventures, Future Ventures, KdT Ventures

Team

Anand Parikh, J.D. (CEO and Co-founder): Former CFO at Virta Health.

Oliver Maddocks, PhD (Head of Research and Co-founder): Professor of Cancer Biology & Metabolism, University of Glasgow

Lew Cantlay, PhD (Co-founder): Director Meyer Cancer Center, Weill Cornell Medicine Founder: Agios (NASDAQ), Petra, Volastra

Greg Hannon, PhD (Co-founder): Director of CRUK (Cancer Rearch UK) Cambridge Institute

Scott Lowe, PhD (Co-founder): Chair of Cancer Biology & Genetics at Memorial Sloan Kettering; Founder: ORIC (NASDAQ)

Sid Mukherjee, MD PhD (Co-founder): Asst. Prof., Columbia; Pulitzer Prize Winner; Time 100 Most Influential People; Founder: Vor (NASDAQ)

Karen Vousden, PhD (Co-founder): Chief Scientist of CRUK; Group Leader, Crick Institute; Director, Bristol Myers Squibb

Marcus Goncalves, MD PhD (Co-founder): Assistant Professor Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine New York

Ben Hopkins, PhD (Co-founder): Asst. Prof., Genetics Genomics & Oncological Sciences, Icahn School of Medicine at Mount Sinai New York

Simon Knott, PhD (Co-founder): Assistant Professor, Biomedical Sciences & Associate Director, Center for Bioinformatics and Functional Genomics, Cedars Sinai Medical Centre Los Angeles

[1] CDC

[2] American Journal of Pathology

Flywheel Exchange, Inc.

Established: 2012
Location: Minneapolis, MN
Prior Round Funding: Series C

Established:
Location:
Prior Round Funding:

Flywheel offers a SaaS platform that provides cloud-scale data management and computational analysis.

Geneoscopy, Inc

Established: 2015
Location: Saint Louis, MO
Prior Round Funding: Series B

Established:
Location:
Prior Round Funding:

Geneoscopy is developing next generation diganostics that use stool-derived RNA to prevent, detect, and guide treatment for gastrointestinal diseases.

Genome Medical, Inc.

Established: 2016
Location: Minneapolis, MN
Prior Round Funding: Series C

Established:
Location:
Prior Round Funding:

GeneMatters is a digital health platform that provides scalable, on-demand genetic counseling to meet the rapidly growing demand for genetic services.

Gila Therapeutics, Inc.

Established: 2014
Location: Minneapolis, MN
Prior Round Funding: Series B

Established:
Location:
Prior Round Funding:

Gila Therapeutics is developing a treatment for obesity using naturally occurring hormones known to induce satiety, leading to weight loss.

Healionics, Inc.

Established: 2007
Location: Seattle, WA
Prior Round Funding: Series A

Established:
Location:
Prior Round Funding:

Healionics, Inc. has developed a novel bio-material called STAR, that features strong anti-infective properties and significant reduction in the formation of scar tissue around implanted medical devices coated with the material.

HepaTx Corp.

Established: 2015
Location: Palo Alto, CA
Prior Round Funding: Seed

Established:
Location:
Prior Round Funding:

HepaTx is a cell therapy company developing stem cell technologies to produce low-cost and scalable sources of liver cells that can be used to preserve or regenerate liver function in patients with liver failure.

Holobiome, Inc.

Established: 2015
Location: Cambridge, MA
Prior Round Funding: Series A

Established:
Location:
Prior Round Funding:

Holobiome is developing a platform for microbiome-based therapeutics to treat diseases of the central and enteric nervous systems.

Immunophotonics, Inc.

Established: 2012
Location: St. Louis, MO
Prior Round Funding: Series B

Established:
Location:
Prior Round Funding:

Immunophotonics has developed a novel polymer that retains cancer antigens after an ablation procedure. Injected into the tumor site after the procedure, it primes the immune system for a systemic wide response to the tumor and its metastases.

MOBILion Systems, Inc.

Established: 2015
Location: Exton, PA
Prior Round Funding: Series A

Established:
Location:
Prior Round Funding:

MOBILion Systems is an analytical instrumentation company using ion mobility to substantially improve the ability to see and identify previously undetectable, clinically significant molecules in minutes.

Molecular Assemblies

Established: 2013
Location: San Diego, CA
Prior Round Funding: Series B

Established:
Location:
Prior Round Funding:

Molecular Assemblies is developing an enzymatic DNA synthesis platform technology. Molecular Assemblies’ novel enzymatic DNA synthesis platform has the potential to fundamentally transform how we write genetic building blocks with applications across food, healthcare, energy, and beyond.

Neuros Medical, Inc.

Established: 2008
Location: Willoughby Hills, OH
Prior Round Funding: Series C

Established:
Location:
Prior Round Funding:

Neuros Medical, a medical device company, develops an electrical nerve block to treat chronic pain for conditions including neuroma/residual limb pain and chronic post-surgical pain.

Nix, Inc.

Established: 2015
Location: Boston, MA
Prior Round Funding: Series A

Established:
Location:
Prior Round Funding:

Nix Biosensors is developing a wearable device and biosensor system platform that monitors hydration in real-time, helping reduce health incidents associated with dehydration while improving performance for athletes, laborers, military personnel and the elderly.

Readout

Established: 2018
Location: St. Louis, MO
Prior Round Funding: Seed

Established:
Location:
Prior Round Funding:

Readout (or The Company) has developed a low-cost breath-analysis device with clinical grade accuracy for measuring blood-ketone levels, an important indicator of a patient’s metabolism.

SciBac, Inc.

Established: 2015
Location: Burlingame, CA
Prior Round Funding: Series A

Established:
Location:
Prior Round Funding:

SciBac is developing a platform technology called MERGE that enables the Company to efficiently combine desired traits of two microbes into one stable hybrid organism through lab-induced directed evolution.